86 results about "Cardiac arrhythmia" patented technology

Devices, systems and methods are provided for treating target tissue with pulsed electric field energy in a manner that does not induce cardiac arrhythmias such as fibrillation of the heart and therefore negates any need for cardiac synchronization of energy delivery. Cardiac synchronization is typically employed to avoid delivering energy during portions of the cardiac cycle that are vulnerable to inducing fibrillation. Thus, herein parameters are manipulated to reduce the probability of inducing an arrhythmia. Typically, high voltage energy can trigger a premature action potential within the cardiac muscle as the delivered energy increases the cardiac muscle cell membrane permeability allowing ion transport, which can induce cardiac arrhythmias, especially ventricular fibrillation. However, both shorter pulse durations (i.e. higher frequencies such as 100-600 kHz) and biphasic waveform shapes theoretically and practically reduce the probability of inducing an arrhythmia.

A wearable defibrillator for use in dry and non-dry locations includes a harness, ECG sensing electrodes, therapy electrodes configured to deliver defibrillating shocks, and a user interface pod configured to be attached to the harness. The user interface pod includes a speaker configured to provide an audible alarm and one or more buttons configured to be pressed by the patient to indicate the patient is conscious. The wearable defibrillator also includes a waterproof or water-resistant control unit configured to determine whether the patient is experiencing a cardiac arrhythmia, issue the audible alarm, and deliver the defibrillating shocks. The wearable defibrillator further includes a connection pod configured to electrically couple the therapy electrodes to the control unit. The user interface pod is configured to be electrically coupled to the control unit via a waterproof removable connector, which forms a water-tight seal with the control unit when connected to the control unit.

The present invention provides methods of treating or preventing atrial fibrillation, atrial flutter, or a combination thereof comprising intravenously administering sotalol hydrochloride to a subject in need thereof. Embodiments of the present invention further provide novel methods of intravenously administering sotalol hydrochloride for example in pediatric patients. The present invention provides a novel intravenous, prophylactic, antiarrhythmic method of sotalol administration.

Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

This application provides a basket catheter, which includes flexible circuit strips, an elastic support, basket electrodes, and a core rod. The flexible circuit strips are respectively arranged on the inner and outer surfaces of the elastic support, and multiple basket electrodes are disposed on the flexible circuit strips. The basket electrodes can be switched between a contracted state and an expanded state by operating the core rod. The basket electrodes on the inner surface of the elastic support are configured not to contact tissue. Accurate localization of key conduction areas through high-density sampling within the cardiac chambers allows for a clearer elucidation of the arrhythmia matrix, thereby providing better mapping and / or ablation results.

Implantable medical devices and methods that utilize a sensing circuit to sense cardiac activity (CA) signals and an accelerometer to obtain accelerometer data. Memory stores program instructions and device parameters associated with a collection of ventricular arrhythmia (VA) therapies. A processor analyzes the CA signals over one or more cardiac beats, determines a VA episode based on the analysis of the CA signals, determines the VA episode to be hemodynamically stable or unstable based on at least one of the accelerometer data or the CA signals, selects a first VA therapy from the collection of VA therapies based on whether the VA episode is hemodynamically stable or unstable, and apply the first VA therapy using at least one of the at least two coils.

The present invention relates to Givinostat hydrochloride monohydrate for use in the treatment of arrhythmogenic cardiomyopathy.

The application discloses an ambulance electrocardiogram data transmission method, device, equipment, medium and product, and belongs to the technical field of medical data remote transmission. The method comprises the following steps: an industrial computer in the ambulance receives vital sign monitoring data from a vital sign monitor; the vital sign monitoring data is converted into an electrocardiogram waveform, and the electrocardiogram waveform is converted into coordinate values for storage; an arrhythmia part in the electrocardiogram waveform is identified; in the case that a network state is normal, the converted coordinate values of the electrocardiogram waveform are sent to a cloud server, and the cloud server is used for sending the received electrocardiogram waveform coordinate values to a hospital client; in the case that the network state is abnormal, the coordinate values corresponding to the arrhythmia part in the electrocardiogram waveform are graded and cached and are transmitted in a delayed manner. The method can improve the transmission efficiency of electrocardiogram data and ensure the integrity of the electrocardiogram data in the case that the network state is abnormal.

The application discloses a magnetocardiogram gradient instrument and an electrocardio collection circuit packaging structure and a signal processing system, relates to the technical field of medical equipment, and realizes high-density integration of hardware and reliable protection through a rigid protection frame formed by a circuit chip, a layer plate structure and a connecting assembly, shortens a signal transmission path, reduces the influence of environmental vibration, dust, moisture and electromagnetic disturbance on a synchronous sampling link, and provides a stable data basis for multi-modal fusion imaging. The signal processing system comprises multi-modal synchronous collection, noise suppression, data fusion imaging and a diagnosis auxiliary module, generates a high-precision space-time dynamic imaging atlas by constructing a cardiac electromagnetic field joint forward model and applying time and space double constraints, and outputs a cardiovascular risk assessment, a cardiac arrhythmia positioning and a myocardial ischemia quantification result in combination with machine learning. The application solves the problems of low integration, poor anti-interference and insufficient single modal detection precision of existing equipment.

The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for evaluating the prognosis of patients with hypertrophic cardiomyopathy and application thereof. The application determines that one or more of 3-hydroxyrilotene, asparagine-lysine, cyclohexylamine, arachidonic acid, aconitic acid, propionyl carnitine, ceramide, tryptophan, 3-hydroxysebacic acid, traumatic acid, phosphatidylcholine, alanine-proline, lysophosphatidylcholine, taurine and S-garlicin cysteine are related to the prognosis of hypertrophic cardiomyopathy, can evaluate the prognosis of patients with hypertrophic cardiomyopathy after undergoing muscle resection of interventricular septum, and shows accurate judgment on all-cause death or rehospitalization, cardiovascular events and postoperative new-onset arrhythmia. Finally, all the prognostic biomarkers are reproduced in an independent cohort, which is helpful for postoperative risk evaluation of patients with hypertrophic cardiomyopathy, has high specificity and high sensitivity.

The present application relates to the technical field of cardiac defibrillation treatment, and particularly relates to a data processing method and system of an automatic external defibrillator. The method comprises the following steps: obtaining a patient help signal through an SOS safety clock and transmitting the signal to a stereoscopic rescue management terminal; performing regional network positioning on the patient help signal through the stereoscopic rescue management terminal to obtain patient help positioning data; performing electrocardiogram monitoring on the patient based on the patient help positioning data using the automatic external defibrillator to obtain initial electrocardiogram data of the patient's heart; performing data preprocessing on the initial electrocardiogram data of the patient's heart to obtain high-quality electrocardiogram data of the patient's heart; performing cardiac fibrillation feature analysis on the high-quality electrocardiogram data of the patient's heart to obtain cardiac fibrillation feature data of the patient; and performing arrhythmia calculation on the cardiac fibrillation feature data of the patient to obtain a cardiac fibrillation arrhythmia index of the patient. The present application can realize accurate defibrillation of the patient's arrhythmia.

The hybrid stimulation system is an electrical stimulation system serves to delivered an electrical stimulation impulse to the heart (human or animal heart) , using a combination of internal (intravascular) and external (body surface) electrodes, the hybrid electrical stimulation system can be used for pacing of the heart during slow heart beat (bradycardia), or shocking the heart during fast heart beat (Tachycardia) , or to terminate fast abnormal heart beat (tachy-arrhythmia) by means of override pacing (Anti-tachycardia pacing). This hybrid system can be used and introduced into the body without the need for imaging guidance such as fluoroscopy or echocardiography to insert the internal component, and does not require direct contact between the internal pacing wire and the myocardium (internal heart surface).

The present invention provides a pharmacological wearable cardioverter defibrillation system for conducting cough assisted pharmacological cardioverter defibrillation during onset of a sudden arrhythmia. The system comprises a WCD defibrillator worn by the patient, a drug mix contained either in a reservoir / pump or in an inhaler, and a miniature monitor. The drug mix in the reservoir / pump is equipped with a pump for pumping the drug mix via an indwelling catheter to the coronary sinus while the drug mix in the inhaler is inhaled directly to the lungs. When a sudden arrhythmia is detected by a sensing electrode of WCD, the following steps are carried out: prompting the patient to take the drug mix, prompting the patient to start forceful coughing, and delivering electric shock(s) under either one of the two circumstances that the patient is unable to start coughing or the arrhythmia is not terminated.

The invention provides compositions and methods for providing a cardioprotective effect in a subject. Specifically, the invention provides compositions and methods for treating cardiovascular ailments, for example, ischemia / reperfusion (I / R) injury, cardiac arrhythmias, oxidative stress, or cardiac failure by administering a retinoic acid receptor-beta (RARβ) agonist.

A cardiac treatment device, including:stimulation circuitry configured to generate a non-excitatory electrical signal which, when applied to ventricular tissue during a ventricular refractory period thereof improves a condition of heart failure in human patients;atrial arrhythmia detection circuitry; anddecision circuitry which controls the stimulation circuitry to delivery said signal, also when said atrial arrhythmia detection circuitry detects an atrial arrhythmia.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The application belongs to the field of heart disease treatment and natural medicine compound, and provides application of bufalin or a pharmaceutically acceptable salt thereof in preparation of a medicine for treating reperfusion arrhythmia. Experiments in vitro and in vivo prove that bufalin inhibits L-type calcium channels in a concentration-dependent manner, reduces extracellular calcium ion inflow, and further reduces the incidence of ventricular arrhythmia, arrhythmia, reduces ventricular conduction time, increases left ventricular conduction velocity, and reduces ventricular conduction dispersion; and provides a new drug selection for the treatment of reperfusion arrhythmia.

The invention provides an implantable wireless electrocardio detection device, and relates to the field of in-vivo implantable devices, the implantable wireless electrocardio detection device comprises a shell and a plurality of electrodes, the plurality of electrodes are arranged on the shell, the monitoring ends of the plurality of electrodes are exposed on the surface of the shell, and the plurality of electrodes are used for collecting subcutaneous electrocardio signals; the circuit board is arranged in the shell, a processor and a memory are integrated on the circuit board, and the electrodes are electrically connected with the memory; the induction coil is arranged in the shell and electrically connected with the circuit board, and the induction coil is configured to receive a wireless pressure signal sent by a blood pressure sensor implanted in the heart; the processor is configured to store wireless pressure signals received by the induction coil and electrocardiosignals collected by the electrodes into the storage. According to the technical scheme, a high-synchronism original data basis is provided for follow-up analysis of the relevance between heart electrical activity and hemodynamics, such as evaluation of the influence of arrhythmia on blood pressure, and the capacity of comprehensive monitoring and diagnosis of cardiovascular diseases is remarkably enhanced.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The present application belongs to the technical field of arrhythmia auxiliary classification, and particularly relates to an arrhythmia classification system based on double-band waveform feature extraction. The system comprises the following steps: extracting a single heartbeat from an original ECG signal to obtain a heartbeat sequence; predicting the probability of each sampling point in the heartbeat sequence belonging to different waveform types, and determining the starting point and ending point of each waveform to further extract key wave components; fusing the key wave components with overall heartbeat morphological features and RR interval information to obtain heartbeat-level feature representation; using a multi-head self-attention mechanism to extract information in different subspaces of the heartbeat-level feature representation, capture inter-beat dependence, and obtain sequence-level feature representation; and based on the sequence-level feature representation, realizing arrhythmia classification of the original ECG signal. The present application designs a heartbeat-level feature extraction stage and an inter-beat feature interaction stage, and uses the two consecutive stages to realize multi-scale feature extraction and inter-beat information interaction, thereby enhancing the abnormal heartbeat recognition capability.

The invention concerns the use of compounds represented by formula (I)as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

The present application relates to the technical field of non-contact vital sign monitoring, and specifically discloses a heart signal detection method based on feature decoupling millimeter wave radar based on contrast learning. The present application realizes the automatic separation of the rhythm feature and the morphological feature of the heart signal from the millimeter wave radar signal by constructing an adaptive filtering module, a sample generator, a multi-scale feature extraction module, a double-path feature decoupling module, a physical constraint module and a contrast learning loss function. The present application uses contrast learning to construct a positive sample pair, guides the model to learn a feature representation that is invariant to heart rate changes and waveform deformation, and combines physiological prior constraints to improve the robustness and interpretability of the features. The present application effectively solves the shortcomings of traditional methods in signal separation, noise suppression and generalization ability, and can be widely applied to heart rate variability analysis, arrhythmia detection and other heart health monitoring tasks.

A technique for monitoring the occurrence of cardiac arrhythmias in patients is disclosed. A computational system generates sample probability values ​​by applying a machine learning model to sample patient data. The machine learning model determines a corresponding probability value indicating the probability of the arrhythmia occurring during each corresponding time window. The computational system outputs a user interface including graphical data based on the sample probability values, and receives instructions via the user interface for selecting a probability threshold for a patient. The computational system receives patient data of the patient and applies the machine learning model to the patient data to determine a current probability value. In response to determining that the current probability exceeds the patient's probability threshold, the computational system generates an alert indicating that the patient may have experienced the occurrence of the arrhythmia.

A medical device is configured to sense one or more cardiac electrical signals and sense a ventricular event signal from the one or more cardiac electrical signals. The medical device can determine that the one or more cardiac electrical signals satisfy a tachyarrhythmia detection criterion, and in response to satisfying the tachyarrhythmia detection criterion, apply a delay criterion to the one or more cardiac electrical signals sensed during each of a plurality of groups of a plurality of sensed ventricular event signals. In response to satisfying the detection delay criterion, the medical device can delay detection of a tachyarrhythmia.

A device configured to be positioned on a limb of a user, includes a physiological sensor configured to generate a cardiac signal characteristic of a user's cardiac activity, an ultrasound transducer configured to generate a Doppler signal characteristic of blood flow in the limb, a control unit configured to: receive a cardiac signal from the physiological sensor, analyze the received cardiac signal, and in response to detection of a suspected cardiac arrhythmia in the cardiac signal analysis, activate the ultrasound transducer to generate a Doppler signal.

To provide medical probes. [Solution] A medical probe may include electrodes for ablation, for sensing proximity to tissue, and / or for monitoring electrical signals within the cardiovascular system to identify aberrant-conducting tissue sites causing arrhythmias. The electrodes may be oriented on an end-effector assembly, such as a basket assembly, so that one side of the electrode is positioned to contact the tissue and the opposite side is prevented from contacting the tissue. To enable both efficient energy delivery and high sensitivity for ECG sensing, an impedance-reducing coating may be positioned on the tissue-contact side, and an impedance-increasing coating may be applied to the opposite side. The impedance-increasing coating on an IRE electrode may be thin enough to allow energy to be delivered through the coating during ablation. An RF electrode may have a mass sufficient to carry electrical energy for thermal ablation.